[Antibodies against hepatitis C virus in patients with liver diseases and in risk subjects. Preliminary report]

Important note: Information in this article was accurate in 1993. The state of the art may have changed since the publication date.

[Antibodies against hepatitis C virus in patients with liver diseases and in risk subjects. Preliminary report]

G E N. 1990 Oct-Dec;44(4):343-8. Unique Identifier : AIDSLINE MED/93083945
Garassini MA; Ortega F; Valdes A; Alvarado M; Cid A; Serrano L; Torres G; Hagen E; Dugarte I; Perez N; Departamento de Gastroenterologia, Hospital Militar Dr. Carlos; Arvelo, Caracas, Venezuela.

Abstract: The recent discovery of an antigenic component of the causative agent of Non-A, Non-B hepatitis, has led to the characterization of this virus--Hepatitis C Virus (HCV)--and to the identification of an antibody present in infected subjects (anti-HCV) detected by means of the C-100 antigen derived from a nonstructural region of the viral genome. Using a commercial Kit (Ortho Diagnostic Inc.), the incidence of anti-HCV antibody was studied in the Military Hospital Dr. Carlos Arvelo of Caracas, Venezuela with the following results: Health personnel (doctors, nurses, laboratory staff): 102 persons studied, 2 positives (1.96%); 16 patients in chronic hemodialysis: 6 positives (33%); 20 subjects with antibodies against HIV virus, confirmed by Western Blot: 7 positives (35.4%). Of 10 patients with Surface Antigen negative Chronic Hepatitis, 7 (70%) positive for anti-HCV, of 25 patients with cirrhosis: 12 positive (48%), 2 patients with hepatocarcinoma 1 positive (50%). There was also a high incidence of total anti-core antibodies in the patients studied. The results suggest that the hepatitis C virus could be playing an important role as a causative factor of liver diseases in our Country.

Keywords: Adult Aged Aged, 80 and over Carcinoma, Hepatocellular/IMMUNOLOGY Chronic Disease English Abstract Female *Health Personnel Hemodialysis Hepatitis Antibodies/*ANALYSIS Hepatitis C/IMMUNOLOGY Hepatitis C Viruses/*IMMUNOLOGY Human HIV Antibodies/ANALYSIS Liver Cirrhosis/IMMUNOLOGY Liver Diseases/*IMMUNOLOGY Liver Neoplasms/IMMUNOLOGY Male Middle Age Risk Factors JOURNAL ARTICLE
930330
M9331090

AEGiS is a 501(c)3, not-for-profit, tax-exempt, educational corporation. AEGiS is made possible through unrestricted funding from Boehringer Ingelheim, Bridgestone/Firestone Charitable Trust, Bristol-Myers Squibb Company, Elton John AIDS Foundation, Gill Foundation, the National Library of Medicine, Quest Diagnostics, Roche and Trimeris, and donations from users like you. Always watch for outdated information. This article first appeared in 1993. This material is designed to support, not replace, the relationship that exists between you and your doctor.

AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.

Copyright ©1980, 1993. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content. .